RA
Vice President, Head of CMC
Get the full picture
Sign in to uncover key details.
Stelexis Therapeutics
Business Services · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
780 3rd Ave Fl 37, New York, New York, 1...Phone Number
(212) 692-7178Website
www.stelexis.comRevenue
<$5 MillionIndustry
About Stelexis Therapeutics
Stelexis BioSciences is a clinical-stage biopharmaceutical company focused on developing novel treatments to eradicate hematological cancers at their root causes. The company addresses significant unmet medical needs in hematological malignancies, including acute myeloid leukemia and myelodysplastic syndromes. Their pipeline aims to induce remissions, prevent relapse, and improve patient outcomes and survival rates. Stelexis BioSciences is dedicated to advancing innovative therapies for patients suffering from these complex conditions.Explore more
Stelexis Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Stelexis Therapeutics
Compare insights from companies similar to Stelexis Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Stelexis Therapeutics
<$5M
1-10
Private
$43M
2017
MP
Marie PaytonSenior VP, Clinical Development Operations
Stelexis Therapeutics Tech Stack
A closer look at the technologies used by Stelexis Therapeutics
See more technologies
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Stelexis Therapeutics
Sign Up For FreeTo access detailed company insights
Stelexis BioSciences is a clinical-stage biopharmaceutical company focused on developing novel treatments to eradicate hematological cancers at their root causes. The company addresses significant unmet medical needs in hematological malignancies, including acute myeloid leukemia and myelodysplastic syndromes. Their pipeline aims to induce remissio... Read More
